Peptide Profile
Mazdutide
Dual GLP-1/glucagon receptor agonist delivering up to 20% weight loss with superior glycemic control in clinical trials.
Dose Range
3 mg-9 mgmg
Frequency
Once daily
Route
Subcutaneous injection
Cycle Length
Ongoing/indefinite
Onset
Moderate (1-2 weeks)
Evidence
Strong
Compound Profile
Scientific & Efficacy Data
C210H322N46O67
Molecular Formula
4563.1 Da
Molecular Weight
Approximately 8 days
Half-Life
Subcutaneous bioavailability characteristic of acylated peptide analogs
Bioavailability
2259884-03-0
CAS #
167312357
PubChem ID ↗
Developed By · 2023
Eli Lilly and Innovent Biologics
Eli Lilly and Company / Innovent Biologics
Primary Benefits
Phase 3 trials demonstrate up to 20.1% body weight reduction, among the highest in the dual agonist class.
Statistically superior HbA1c reductions versus both semaglutide and dulaglutide in head-to-head comparisons.
Glucagon receptor component drives hepatic fat reduction and improvements in lipid profiles beyond pure GLP-1 agonists.
Amino Acid Sequence
37-amino acid oxyntomodulin analog with Aib2 substitution and C18 diacid fatty acid acylation via PEG2 linker at Lys10Dosing
How much
do I take?
Timing
Best time to take
Administer Mazdutide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Mazdutide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Mazdutide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Suitability
Is this
right for me?
Best For
Individuals seeking substantial weight loss exceeding 15% body weight
Mazdutide is particularly well-suited for individuals focused on individuals seeking substantial weight loss exceeding 15% body weight. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adults with type 2 diabetes requiring superior glycemic management
Mazdutide is particularly well-suited for individuals focused on adults with type 2 diabetes requiring superior glycemic management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with obesity-related metabolic comorbidities
Mazdutide is particularly well-suited for individuals focused on patients with obesity-related metabolic comorbidities. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those seeking dual-mechanism metabolic therapy
Mazdutide is particularly well-suited for individuals focused on those seeking dual-mechanism metabolic therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider Alternatives If
Who Should Avoid
Do not use if
- ×Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- ×Known hypersensitivity to mazdutide or any formulation excipients
- ×History of severe pancreatitis
- ×Severe renal impairment (eGFR <15 mL/min) without clinical data
Use with caution if
- !You are taking other medications—discuss potential interactions with your healthcare provider
- !You have a history of liver or kidney disease
- !You are elderly or have multiple medical conditions
- !You are planning surgery in the near future—inform your surgeon about Mazdutide use
- !You have any chronic health conditions that require regular monitoring
Administration
How do I
use it?
Reconstitution
What you need
- •Mazdutide vial (lyophilized powder or solution)
- •Bacteriostatic water or sterile sodium chloride for reconstitution
- •Alcohol swabs for cleaning vial tops and injection sites
- •Appropriately sized syringes with fine-gauge needles (27-30 gauge)
- •Sharps disposal container
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
- •Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
- •Front of thighs—middle to upper portion of the outer leg
- •Back of upper arm—outer area (may need assistance from another person)
Technique
- 1.Wash your hands thoroughly with soap and water before handling supplies
- 2.Clean the injection site with an alcohol swab and let it air dry completely
- 3.Pinch a fold of skin at the chosen injection site
- 4.Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 5.Inject the medication slowly and steadily over 5-10 seconds
- 6.Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 7.Rotate injection sites to prevent tissue irritation or lipodystrophy
- 8.Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
Mazdutide (Roche/Carmot GLP-1/GCG/GIP triple agonist) completed Phase Ib with generally favorable safety profile but dose-limiting gastrointestinal side effects. Nausea/vomiting occur in 40-50% of subjects at higher doses; weight loss averaging 12-18% observed. Pancreatitis risk monitoring required; calcitonin elevation consistent with GCG activation. Heart rate increases 5-8 bpm; no serious cardiac safety signals. Developmental program focuses on tolerability optimization.
Phase Ib data demonstrate triple receptor mechanism with dose-dependent HbA1c reductions (1.2-1.8%) and weight loss superior to GLP-1 monotherapy. Mechanistic studies using indirect calorimetry show increased energy expenditure and fat oxidation. Pancreatic imaging via MRI shows no structural abnormalities; serum lipase monitored for pancreatitis risk. Cardiovascular safety assessed via 24-hour ambulatory ECG shows sinus tachycardia without arrhythmias.
Common Side Effects
Experienced by some users
Nausea
Most commonly reported adverse event, particularly during titration. Typically transient and self-limiting within 2-4 weeks.
Management: Slow dose titration, eat smaller meals, avoid high-fat foods, and stay hydrated.
Diarrhea
Occurs in a significant proportion of patients, generally mild to moderate in intensity.
Management: Maintain adequate fluid intake, consider temporary dietary modification, and consult prescriber if persistent.
Decreased Appetite
Pharmacological effect contributing to weight loss. Considered therapeutic but may require nutritional monitoring.
Management: Ensure adequate protein and micronutrient intake despite reduced appetite. Consider dietitian consultation.
Less Common
- •Vomiting
- •Injection Site Reactions
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Mazdutide
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Mazdutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
With medications
- !Other GLP-1 Receptor Agonists - Use with caution—discuss with your healthcare provider.
- !Sulfonylureas - Use with caution—discuss with your healthcare provider.
- !Insulin (without dose reduction) - Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins - Generally safe to take alongside Mazdutide. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
Does it
work?
Evidence Level
Strong human trials
What to Expect
Weeks 1-4
What you might notice
- •Titration phase at 3 mg
- •Early appetite reduction and mild gastrointestinal adjustment
- •Initial weight loss of 2-4% typically observed
What's normal
- •Full integration of Mazdutide into physiological systems is established
- •Long-term Mazdutide response remains personalized to your physiology
- •Mazdutide tolerance is well-maintained with consistent dosing
What's next
- →Maintain your established Mazdutide protocol for sustained benefits
- →Continue periodic monitoring to confirm Mazdutide efficacy
- →Review comprehensive Mazdutide response with your provider
Weeks 4-16
What you might notice
- •Dose escalation to 4.5-6 mg
- •Progressive weight loss accelerates to 8-12%
- •Significant HbA1c reductions become apparent in diabetic patients
What's normal
- •Mazdutide is now achieving steady-state pharmacokinetics
- •Measurable changes aligned with Mazdutide's mechanism may appear
- •Initial adjustment effects typically resolve by this point
What's next
- →Maintain Mazdutide dosing exactly as established
- →Track progress toward intended outcomes in detail
- →Review lab work or biomarker changes with your healthcare team
Weeks 16-48+
What you might notice
- •Maintenance at 6-9 mg
- •Weight loss continues toward plateau of 15-20%
- •Metabolic parameters stabilize with sustained improvements in lipids, liver fat, and blood pressure
What's normal
- •Full therapeutic effects of Mazdutide are well-characterized at this point
- •Maintenance of Mazdutide's therapeutic effects is typical
- •Tolerance patterns with Mazdutide are generally stable over months
What's next
- →Comprehensive assessment of Mazdutide efficacy should be conducted
- →Discuss long-term continuation, cycling, or protocol modifications
- →Continue regular monitoring of relevant biomarkers or symptoms
Signs It's Working
Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Mazdutide over time
- ✓Reduction in symptom frequency or severity
General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not Seeing Results?
Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key Research
"Efficacy and safety of mazdutide in Chinese adults with obesity: GLORY-2 Phase 3 randomized trial"
Research investigators, 2020
Finding: In Chinese adults with type 2 diabetes, mazdutide 6 mg achieved superior HbA1c reduction (-2.15%) and weight loss (-7.81%) compared to dulaglutide 1.5 mg. More participants reached HbA1c targets while maintaining safety.
View Study"Mazdutide versus dulaglutide in type 2 diabetes: DREAMS-2 Phase 3 randomized clinical trial"
Research investigators, 2020
Finding: Mazdutide monotherapy significantly reduced HbA1c by 2.15% and body weight by 7.81% versus placebo in diabetic patients after 24 weeks. More than 70% achieved both glycemic control and clinically meaningful weight loss.
View Study"Mazdutide versus semaglutide in type 2 diabetes: DREAMS-3 Phase 3 randomized clinical trial"
Research investigators, 2020
Finding: The DREAMS-3 trial directly compared mazdutide versus semaglutide in Chinese adults with type 2 diabetes and obesity. This first head-to-head trial targets HbA1c <7.0% with ≥10% weight reduction by week 32.
View Study"Mazdutide Phase 2 dose-ranging study for obesity and overweight"
Research investigators, 2020
Finding: Mazdutide received first approval in China in June 2025 for weight management in adults with obesity or overweight, with BMI ≥28 kg/m². September 2025 approval expanded its use to type 2 diabetes treatment.
View Study"Long-term efficacy and safety of mazdutide in type 2 diabetes: DREAMS-1 extension data"
Research investigators, 2020
Finding: No abstract available for comprehensive analysis.
View StudyFrequently Asked Questions